P. Makrantonakis

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

George Fountzilas, Dimosthenis Skarlos, Urania Dafni et al. · Annals of Oncology · 2005 · 100 citations · Full text

Medicine, Oncology, Pharmacology +12

Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group

George Fountzilas, Haralabos P. Kalofonos, Urania Dafni et al. · Annals of Oncology · 2004 · 69 citations · Full text

Medicine, Oncology, Pharmacology +9

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00

George Fountzilas, Urania Dafni, Helen Gogas et al. · Annals of Oncology · 2007 · 47 citations

Medicine, Oncology, Pharmacotherapy +14

Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG)

Emmanouil Saloustros, Nikolaos Malamos, Ioannis Boukovinas et al. · Breast Cancer Research and Treatment · 2014 · 18 citations

Medicine, Oncology, Pharmacology +12

Cyclophosphamide, Mitoxantrone, Fluorouracil versus Conventional CMF as Adjuvant Treatment in Node-Positive Breast Cancer Patients

George Fountzilas, A. Polichronis, K Katsohis et al. · Oncology · 2009 · 12 citations · Full text

Medicine, Oncology, Pharmacology +14